News | February 04, 2008

Drs. Perform First Mitralign Percutaneous Annuloplasty System Implant

February 5, 2008 – A medical team led by Adrian Ebner, M.D., of French Hospital and Lutz Buellesfeld, M.D. of Helios Heart Center, Siegburg, Germany, performed the first implantation of the Mitralign Percutaneous Annuloplasty System for mitral valve repair at French Hospital in Asuncion, Paraguay.

The Mitralign System was able to remodel the valve and reduce the patient’s mitral regurgitation from 3 to 2 , 24 hours after the procedure based on core lab assessment. The patient spent less than 48 hours in the hospital after the procedure and continues to do well at home.

The Mitralign System emulates the open surgical procedure of suture-based mitral annuloplasty. The implant was percutaneously delivered through a single 14F femoral arterial sheath, and provides direct geometric reduction of the posterior annulus. commented on the system’s clear impact on the mitral valve geometry.
"I have been involved with a number of mitral valve repair approaches; this approach is most exciting because it delivers on its promise to affect the valve on demand," said Dr. Ebner.

The case will be presented at two conferences this month, Cardiovascular Revascularization Therapies in Washington, D.C., by Prof. Dr. med. Eberhard Grube and the Joint Interventional Meeting, in Rome, Italy, by Paul Teirstein, M.D.

For more information: www.mitralign.com


Additional Content

News | Heart Valve Technology

Oct. 29, 2026 — Abbott has initiated the CROWN-MV pivotal trial evaluating the safety and effectiveness of its ...

Home November 05, 2026
Home
News | Heart Valve Technology

Oct. 21, 2026 — Edwards Lifesciences Corp. recently announced that the U.S. Food and Drug Administration (FDA) has ...

Home October 23, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Following transcatheter aortic valve implantation (TAVI), disturbances in the heart’s electrical ...

Home September 25, 2026
Home
News | Heart Valve Technology

Sept. 22, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai have received a $3.6 million, four-year ...

Home September 24, 2026
Home
News | Heart Valve Technology

June 29, 2026 — Laplace Interventional recently announced that the U.S. Food and Drug Administration (FDA) has approved ...

Home July 02, 2026
Home
Subscribe Now